AVID 18F-AV-1451

AVID 18F-AV-1451 / A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

Description

The purpose of this study is to see how well the investigational drug 18F-AV-1451 used as a brain imaging drug in positron emission tomography (PET). PET is a way to look at a picture of the inside of the body. 18F-AV-1451 works in the detection of protein deposits in the brain. 18F-AV-1451 sticks to a special type of protein in the brain called tau protein and can be seen in pictures taken using a PET/CT scanner. This protein has been linked to people who have dementia or Alzheimer’s disease or may develop Alzheimer’s disease. Pictures of the brain made using the study drug during the life of study participants will be compared to results of brain autopsy after death. Autopsy is the examination of the body or body parts after death.

 Eligibility

  • Men and Women
  • Age 50 years old and older  
  • Have a projected life expectancy of 6 months or less

 Requirements

  • Tests of memory and thinking skills
  • Have a study partner – a friend or relative who can accompany the volunteer to clinic visits
  • Consent to brain donation upon death

 Participant Benefits

  • Compensation for time and travel

Contact Information:

Tim Collare:  336-716-6463

 

Last Updated: 07-13-2016
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.